Short answer
No cannabis, CBD, or THC product holds FDA approval to treat autism spectrum disorder (ASD). Clinical evidence comes from small trials, most of them open-label. State medical cannabis programs decide who can get a card. Use in children happens off-label under a physician's care.
How common is autism
The CDC's monitoring network estimated 1 in 36 children aged 8 years had ASD in the 2020 surveillance year. The 2018 estimate was 1 in 44. Boys are diagnosed about 3.8 times as often as girls. Sleep problems, anxiety, and irritability are reasons families ask about treatment.
What the trials measure
Researchers use caregiver questionnaires and clinician rating scales. Endpoints include social communication, repetitive behavior, hyperactivity, and sleep. Products differ between studies. Some are CBD-rich extracts with a small amount of THC. Some are CBD isolate. Doses vary.
Understanding the Role of Marijuana for Autism
Largest published study
A 2021 retrospective study in Molecular Autism followed 150 people with ASD in Israel. Mean age was 11 years. Treatment was a CBD-rich extract at a CBD to THC ratio near 20 to 1. Caregivers reported change on social communication and behavior scores after 6 months. Side effects were reported in about one third of participants. Drowsiness and appetite loss were the most cited. The study had no placebo group, so placebo response and caregiver expectation can explain part of the change.
What reviews conclude
Reviews of the cannabis and autism literature rate the evidence as low certainty. Reasons include small samples, no blinding, short follow-up, and no standard product. No trial has shown that cannabis treats the core features of ASD, which are social communication differences and restricted or repetitive patterns of behavior.
Safety concerns
- Liver injury. The FDA has warned about CBD-linked liver damage, with higher risk at higher doses.
- Drowsiness and sedation.
- Appetite loss and diarrhea.
- Drug interactions. CBD raises blood levels of clobazam and valproate, two drugs used in seizure disorders, and affects other drugs that share the same liver enzymes.
- THC effects on a developing brain include problems with memory and attention, plus a higher risk of psychosis in people with a family history.
State law
Rules differ by state. Some programs list ASD or a related diagnosis, such as a seizure disorder. Others do not. Pediatric patients need a physician certification in most states, and a parent or guardian registers as the caregiver. CBD sold online is not the same product as state medical cannabis. The FDA does not allow CBD in dietary supplements or food.
Questions to ask a clinician
- Which symptom are we targeting, and how will we score it?
- What dose, product type, and schedule?
- Does the product have a lab report for potency, pesticides, and solvents?
- What interactions with current prescriptions?
- What side effects signal that we stop?
Bottom line
Evidence for cannabis in autism is thin. No product is FDA-approved for ASD. Small studies report gains on behavior scores, and none proves cause and effect. Families who pursue it do so under state law, with a physician, one target symptom, and a written plan to track results and side effects.